Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?

Fox, K A A

Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? [electronic resource] - European heart journal 05 2019 - 1466-1471 p. digital

Publication Type: Comparative Study; Journal Article

1522-9645

10.1093/eurheartj/ehy347 doi


Aspirin--adverse effects
Atherosclerosis--complications
Chronic Disease
Clinical Trials as Topic
Death
Drug Therapy, Combination
Factor Xa Inhibitors--adverse effects
Fibrinolytic Agents--adverse effects
Hemorrhage--chemically induced
Humans
Myocardial Infarction--epidemiology
Platelet Aggregation Inhibitors--adverse effects
Rivaroxaban--adverse effects
Secondary Prevention--methods
Stroke--epidemiology
Thrombosis--prevention & control
Vascular Diseases--pathology